GlassScriptPhysician profile
Aaron L Tang
NPI 1841456522
$3,293.02
in general payments reported to CMS, 2019-2025
21 companies · $240 in 2025
The $240 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $123 · 2020: $14.06 · 2021: $327 · 2022: $430 · 2023: $1,039 · 2024: $1,121 · 2025: $240.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,399.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,398.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $706.88 | 2021-2024 | Farxiga, Brilinta |
| Abbott Laboratories | $452.68 | 2022-2025 | Amplatzer Amulet, Jot Dx, Merlin@Home |
| Pfizer INC. | $330.19 | 2019-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $313.28 | 2021-2024 | Lifevest |
| Boston Scientific Corporation | $271.25 | 2022-2025 | Watchman Access System |
| Novo Nordisk INC | $255.59 | 2023-2024 | Wegovy, Rybelsus, Ozempic |
| Novartis Pharmaceuticals Corporation | $192.61 | 2022-2024 | |
| Amgen INC. | $160.20 | 2022-2025 | Repatha, Repatha |
| Lantheus Medical Imaging, INC. | $136.11 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $103.87 | 2022-2024 | Verquvo |
| Kestra Medical Technology Services, INC. | $73.31 | 2024-2025 | Assure Wcd |
| Abiomed | $67.30 | 2023-2024 | Impella |
| Esperion Therapeutics, INC. | $58.43 | 2023-2024 | Nexletol |
| E.R. Squibb & Sons, L.L.C. | $29.75 | 2023 | Eliquis |
| Abbvie INC. | $27.22 | 2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cordis US Corp. | $23.96 | 2023 | Mynx Control |
| Actelion Pharmaceuticals US, INC. | $20.73 | 2022 | |
| Alnylam Pharmaceuticals INC. | $19.42 | 2024 | Onpattro |
| Edwards Lifesciences Corporation | $19.23 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Scpharmaceuticals INC. | $17.55 | 2023 | |
| Exact Sciences Corporation | $13.46 | 2024 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Tang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.